BIOMX APPOINTS MICHAEL OSTER AS CEO AND DAVID ROKACH AS CFO TO DRIVE NEXT GROWTH STAGE

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: Mar 09 2026

0mins

PHGE-1.91%

Should l Buy PHGE?

Source: moomoo

New Executive Appointments: Michael Oster has been named Chief Executive Officer, while David Rokach takes on the role of Chief Financial Officer.
Focus on Growth: The new leadership aims to support the next phase of growth for the organization.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PHGE?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PHGE

Wall Street analysts forecast PHGE stock price to rise

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.620

Low

26.00

Averages

26.00

High

26.00

Current: 4.620

Low

26.00

Averages

26.00

High

26.00

H.C. Wainwright

Joseph Pantginis

Buy -> Neutral

downgrade

2026-03-09

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

AI Analysis

2026-03-09

downgrade

Buy -> Neutral

Reason

H.C. Wainwright analyst Joseph Pantginis downgraded BiomX to Neutral from Buy. BiomX has "had a rough time as of late," says the analyst, who notes that both the CEO and Chairman of the Board resigned from the company on March 6, adding "further concern about the potential path forward for the company."

H.C. Wainwright

Joseph Pantginis

Buy

upgrade

$15 -> $26

2025-11-25

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$15 -> $26

2025-11-25

upgrade

Buy

Reason

H.C. Wainwright analyst Joseph Pantginis adjusted the firm's price target on BiomX to $26 from $15 and keeps a Buy rating on the shares. The adjusted target follows the company's reverse stock split.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHGE

Unlock Now

About PHGE

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

BiomX Appoints Dr. Ehud Levi to Advisory Board

9 hours agoNewsfilter

Advisory Board Formation: BiomX has appointed Dr. Ehud Levi to its newly formed Advisory Board, aimed at evaluating and pursuing strategic opportunities in security and defense, particularly in counter-UAS technologies, which is expected to drive the company's expansion in these markets.
Extensive Security Experience: Dr. Levi brings over three decades of experience in Israeli intelligence and national security, having served in Unit 8200 of the Israel Defense Forces and as Head of the Counter-Terror Finance Office, providing deep industry insights and strategic guidance for the company.
Addressing Emerging Threats: With the rapid advancement of UAV technology, Dr. Levi will assist BiomX in identifying and assessing potential partnerships and transactions related to counter-UAS, enhancing the company's competitiveness in the global security landscape.
Clear Strategic Direction: Dr. Levi emphasizes the opportunities at the intersection of national security and technology, stating his commitment to support BiomX in positioning itself within defense systems and security infrastructure, helping the company seize opportunities in a rapidly evolving market.

BiomX Faces Compliance Warning from NYSE

3 days agoseekingalpha

Compliance Warning: BiomX has received a notice from NYSE American LLC for failing to meet minimum stockholders' equity requirements, which involves multiple thresholds ($2M, $4M, $6M) tied to recurring net losses, indicating the company's financial vulnerability.
Compliance Plan Requirement: The company must submit a compliance plan by April 24, 2026, to regain compliance by September 25, 2027; if accepted, it will undergo periodic and quarterly monitoring by NYSE American, highlighting the stringent regulatory scrutiny the company faces.
Potential Delisting Risk: Failure to submit or execute the compliance plan could lead to delisting proceedings, although appeals are permitted, reflecting the pressure on the company to maintain its listing status, which may affect investor confidence.
Current Trading Status: Despite the notice, BiomX's shares will continue to trade, indicating that there is no immediate impact on the market; however, the company previously disclosed a going concern audit opinion in its 2025 annual report, suggesting risks to its long-term financial health.

Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates

5 days agoBarron's

Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.

BiomX Implements Strategic Restructuring to Drive Growth

Mar 19 2026Newsfilter

Leadership Restructuring: BiomX has undertaken significant leadership changes over the past few weeks, aiming to enhance operational efficiency by clarifying strategic priorities and improving financial structure, thereby laying the groundwork for future growth opportunities.
Warrant Adjustment: The company has decided to shorten the original five-year warrant term to one year with an adjusted exercise price of $1.00 per share, a change that will significantly reduce potential market overhang on the company's stock and boost investor confidence.
Cost Control Measures: BiomX is actively reducing non-essential expenses and plans to close its Maryland facility to lower operational costs, which will help enhance the company's financial flexibility and support the implementation of its long-term strategy.
Capital Market Engagement: The company has increased its engagement with capital markets, actively communicating with investment banks and institutional investors to explore potential strategic opportunities, ensuring effective capital access for future business development.

BiomX Appoints New CEO and CFO to Drive Growth

Mar 09 2026seekingalpha

Executive Appointments: BiomX announced the appointment of Michael Oster as CEO and David Rokach as CFO, aiming to leverage their extensive experience to drive the company's strategic growth.
Oster's Background: Michael Oster brings in-depth knowledge of corporate strategy, mergers, and operational leadership, currently serving as CEO of Saffron Tech and a board member of BladeRanger, which is expected to inject new growth momentum into BiomX.
Rokach's Experience: David Rokach has over 20 years of finance and corporate leadership experience, having previously served as CEO of Newcom Finance and Granit Investment Company, providing robust financial management support for BiomX.
Strategic Implications: This executive transition reflects BiomX's commitment to enhancing corporate governance and financial stability, aiming to leverage the new leadership team's expertise to drive growth in capital-intensive sectors.